This Article


Creative Commons License
Except where otherwise noted, this work is licensed under Creative Commons Attribution-NonCommercial 4.0 International License.

Diagnosis and Staging of Hepatocellular Carcinoma

1 Division of Abdominal and Cardiothoracic Imaging, Massachusetts General Hospital, Boston
*Corresponding author: Amir H Davarpanah, MD, Division of Abdominal and Cardiothoracic Imaging, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, E-mail:
Iranian Journal of Radiology. 2017 May; Special iss(5): e48398 , DOI: 10.5812/iranjradiol.48398
Article Type: Abstract; Received: Dec 21, 2016; Accepted: Feb 8, 2017; epub: Apr 13, 2017; ppub: May 2017


Hepatocellular carcinoma (HCC) is the fifth most common tumor in the world, and its incidence is increasing. It is second most common cause of cancer related death worldwide and fastest growing cause of cancer death in the United States. Cirrhosis is the most important clinical risk factor for HCC, with approximately 80% of cases of HCC developing in patients with a cirrhotic liver. HCC differs from most malignancies because it is commonly diagnosed on the basis of imaging features alone, without histologic confirmation. The prognosis of HCC depends largely on the stage at which the tumor is detected. The detection of HCC early in its development, therefore, is critical to improve the survival of affected patients. In this talk, we discuss surveillance strategies with ultrasonography (US) as the primary screening imaging test as well as current state of the art for the imaging-based diagnosis and staging of HCC.

This is an abstract presented in the 33rd Iranian congress of radiology (ICR) and the 15th congress of Iranian radiographic science association (IRSA).